Early stage melanoma refers to skin cancer that remains confined to the skin and has not spread to lymph nodes or distant organs, and it carries a survival rate well above 90 percent when caught and treated promptly. The staging system groups these tumors largely by how deep they grow into the skin and whether the surface is ulcerated. But “early stage” is not one thing: it spans tumors thinner than a millimeter all the way to thicker lesions that still qualify as localized, and the treatment decisions, follow-up intensity, and even psychological burden vary considerably across that range.
What Counts as Early Stage
Melanoma staging follows the American Joint Committee on Cancer (AJCC) system, now in its eighth edition. The primary tumor category, called the T stage, is defined by Breslow thickness, which is the depth of the tumor measured in millimeters, along with the presence or absence of ulceration. Tumors up to 1.0 mm thick are T1, those between 1.01 and 2.0 mm are T2, those between 2.01 and 4.0 mm are T3, and anything thicker than 4.0 mm is T4. Thickness is measured to the nearest 0.1 mm in the current edition.
Within T1, the system draws a further line. T1a melanomas are less than 0.8 mm thick and not ulcerated. T1b includes those 0.8 to 1.0 mm thick regardless of ulceration and those under 0.8 mm that are ulcerated. That 0.8 mm cutoff replaced an older reliance on mitotic rate as the key divider, after analyses showed that thickness and ulceration were stronger predictors of melanoma-specific survival.1PubMed Central. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care Stages I and II encompass tumors that are localized to the skin with no evidence of spread to nearby lymph nodes or beyond. Stage I includes T1 and some T2 melanomas, and stage II extends up through T4 when no lymph node involvement is found. Most people searching for “early stage melanoma” are dealing with something in the stage I or IIA range, but stage IIB and IIC, while still localized, carry enough recurrence risk that they now qualify for systemic treatment.
Spotting It Early
The classic teaching tool for melanoma recognition is the ABCDE checklist: asymmetry, border irregularity, color variation, diameter greater than 6 mm, and evolving appearance. It works well enough as a starting framework, but dermatologists increasingly emphasize the “ugly duckling” sign, the idea that a suspicious mole is one that looks different from its neighbors rather than one that ticks particular shape or color boxes. A study examining how well people detect melanoma after being trained in either approach found that both produced similar sensitivity, meaning they caught a comparable share of real melanomas, but the ugly duckling approach produced significantly better specificity and accuracy, meaning fewer false alarms.2PubMed. The role of the ugly duckling sign in patient education In practice, both strategies complement each other: the ABCDE criteria help you evaluate a single lesion, while the ugly duckling concept helps you scan your entire body for outliers.
Dermatologists also use dermoscopy, a handheld tool that magnifies the skin surface with polarized light, and reflectance confocal microscopy (RCM), which goes a step further by providing near-cellular-level resolution without cutting the skin. RCM has found a growing niche in evaluating ambiguous lesions, mapping the edges of large melanomas on cosmetically sensitive areas like the face, and monitoring treatment response.3PubMed Central. Advances in the use of reflectance confocal microscopy in melanoma For everyday screening, though, the combination of a trained eye, a dermatoscope, and a low threshold for biopsy remains the standard approach.
When a Diagnosis Is Not Straightforward
One underappreciated challenge is that early melanomas can be hard to distinguish from atypical (dysplastic) moles, even under a microscope. Very thin or early melanocytic lesions sometimes fall into a diagnostic gray zone where they do not clearly meet all the criteria for malignancy. Agreement between expert pathologists on these borderline cases is not always strong, and even the same pathologist reviewing the same slide at different times may reach different conclusions.4PubMed. Dysplastic melanocytic nevus: Are molecular findings the key to the diagnosis? This ambiguity can lead to patient anxiety and sometimes to treatment decisions that are more aggressive or more conservative than the biology of the lesion warrants. Molecular testing is one avenue researchers are exploring to bring more objectivity to these borderline calls, though it has not yet replaced the pathologist’s assessment as the standard.
The superficial spreading subtype is the most common form of melanoma and tends to grow outward across the skin surface for months before invading deeper layers. In contrast, nodular melanoma grows vertically early and may reach a dangerous thickness much faster, with a typical duration of only about five months from first notice to diagnosis compared with roughly nine months for superficial spreading melanoma.5PubMed Central. Changes in the presentation of nodular and superficial spreading melanomas over 35 years Nodular melanoma does not always follow the ABCDE pattern either; it frequently presents as a symmetric, uniformly dark or even skin-colored bump. That is part of why relying on a single detection method can miss the melanomas that matter most.
Artificial Intelligence in Melanoma Detection
AI-based tools that analyze dermoscopic images have improved rapidly in recent years and can match or exceed dermatologist performance in classifying lesions as benign or malignant.6PubMed Central. The Role of Artificial Intelligence in the Diagnosis of Melanoma A systematic review of studies directly comparing AI algorithms to dermatologists on dermoscopy images reported a mean algorithm sensitivity of about 83 percent and specificity of roughly 86 percent, with all comparative studies finding AI performance to be equivalent or superior.7PubMed Central. Analysis of Artificial Intelligence-Based Approaches Applied to Non-Invasive Imaging for Early Detection of Melanoma: A Systematic Review These numbers are encouraging, but most of the validation has occurred on curated image datasets rather than in messy real-world clinical settings. The most realistic near-term role for AI is as a triage layer, flagging lesions that deserve a closer look rather than replacing the clinician’s judgment outright.
Surgery for Early Stage Melanoma
Surgery is the primary treatment for early melanoma and, for many patients, the only treatment they will need. The initial step is usually an excisional biopsy, which removes the suspicious lesion along with a small margin of normal-looking skin. If melanoma is confirmed, a wider local excision (WLE) follows to remove additional tissue around the biopsy site. Standard guidelines call for margins of 1 cm for melanomas up to 1 mm thick and 1 to 2 cm for melanomas between 1 and 2 mm thick.
There is growing evidence that the margins currently recommended may be more generous than strictly necessary. A systematic review looking at narrower-than-standard excision margins for melanomas up to 4 mm thick found no worsening of local recurrence, disease-free survival, or overall survival.8PubMed Central. Narrow Excision Margins for Diverse Histological Subtypes of Cutaneous Melanoma in Children and Adults: A Systematic Review A large population-based study went further, reporting that residual tumor in the wider excision specimen was found in fewer than 3 percent of cases for melanomas up to T2, raising the question of whether the second wider excision might be safely omitted for these thinner tumors altogether.9PubMed. Evaluation of residual tumour in wide local excision for melanoma: A nationwide population-based study These findings are influencing ongoing clinical trials, but current guidelines have not yet been formally revised, so the standard wider excision remains the default for now.
Melanoma in situ, where abnormal cells are confined entirely to the top layer of skin, presents its own surgical challenge. Most guidelines recommend 5 to 10 mm margins, but the lentigo maligna subtype, which typically appears on chronically sun-damaged skin of the head and neck, has a notorious tendency to extend microscopically beyond its visible borders. Available data consistently show that margins greater than 5 mm and often greater than 10 mm are needed to achieve clear histologic margins for lentigo maligna.10PubMed Central. Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations When surgical margins remain persistently positive and further excision is impractical, topical imiquimod cream applied along the incision line has been used as an alternative approach in selected patients.11PubMed Central. Melanoma in Situ Treated with Topical Imiquimod for Management of Persistently Positive Margins: A Review of Treatment Methods
Sentinel Lymph Node Biopsy
Sentinel lymph node biopsy (SLNB) has been used in melanoma care for roughly three decades. The procedure identifies and removes the first lymph node or nodes to which a tumor would drain, offering staging information with relatively low surgical risk.12PubMed Central. Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View Whether you are offered SLNB depends on the thickness and features of your melanoma. For very thin melanomas classified as T1a (under 0.8 mm without ulceration), sentinel node biopsy is not routinely recommended because the chance of spread is extremely low. For T1b melanomas (0.8 to 1.0 mm, or thinner with ulceration), it may be considered after discussion. For intermediate-thickness melanomas (greater than 1.0 to 4.0 mm), it is recommended.13PubMed. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update A positive sentinel node upstages the melanoma to stage III, which changes both the prognosis and the treatment plan.
Gene Expression Profiling
Staging by thickness and ulceration does a reasonable job of predicting outcomes for groups of patients, but it is less precise for any individual. A stage I melanoma can still recur, and a stage II melanoma can still be cured by surgery alone. Gene expression profiling (GEP) tests aim to sharpen that prediction by analyzing the tumor’s molecular behavior.
The most commercially available test, a 31-gene expression profile, sorts patients into low-risk (Class 1) and high-risk (Class 2) categories for metastasis, with further subdivisions of 1A, 1B, 2A, and 2B representing a gradient from lowest to highest risk. A large meta-analysis has shown consistent association between these scores and melanoma relapse.14PubMed Central. The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment A combined clinicopathologic and gene expression model (CP-GEP) tested on stage I and IIA patients stratified them into groups with meaningfully different five-year relapse-free survival, roughly 93 percent for the low-risk group versus about 78 percent for the high-risk group.15PubMed. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)
A separate gene expression signature developed from a large melanoma cohort found that among stage II patients, those with a high-risk molecular profile had roughly a 33 percent chance of dying within five years, while those with a low-risk profile had about a 14 percent chance.16Nature Communications. Tumour gene expression signature in primary melanoma predicts long-term outcomes These tools are not yet used to decide whether someone gets treatment versus none, but they are increasingly informing decisions about surveillance intensity and eligibility for adjuvant therapy trials.
Adjuvant Immunotherapy for Higher-Risk Stage II
For years, patients with stage IIB or IIC melanoma, tumors that are thicker or ulcerated but still localized, faced a frustrating paradox: their five-year recurrence risk was substantial, yet no systemic treatment was approved for them after surgery. That changed with the KEYNOTE-716 trial, which tested pembrolizumab, an immune checkpoint inhibitor, against placebo in patients with resected stage IIB or IIC melanoma.
At a median follow-up of about 53 months, pembrolizumab reduced the risk of recurrence by about 38 percent and the risk of distant metastasis by about 41 percent. At the four-year mark, recurrence-free survival was 71.3 percent in the pembrolizumab group versus 58.3 percent with placebo, and distant metastasis-free survival was 81.0 percent versus 70.1 percent.17PubMed. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study The benefit held up across different histologic subtypes of melanoma.18PubMed Central. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
This represents a genuine shift in care, but it comes with trade-offs. Pembrolizumab is given for about a year as an intravenous infusion and can cause immune-related side effects, including thyroid problems, inflammation of the colon or liver, and skin reactions. For a disease where roughly six or seven out of ten patients in the placebo group still had not recurred at four years, the decision about whether to accept a year of treatment and its side effects is deeply personal. Whether pembrolizumab ultimately improves overall survival, not just the time to recurrence, is still being studied.
UV, Genetics, and Risk
Ultraviolet radiation from the sun is the most modifiable melanoma risk factor, but its relationship with melanoma is not as simple as “more sun equals more cancer.” Variants in the MC1R gene, which strongly influence red hair, fair skin, and freckling, interact with sun exposure in complex ways. One pooled analysis found a significant additive interaction between high-risk MC1R variants and a history of many sunburns, meaning the combination of the two amplified melanoma risk beyond what either factor alone would predict.19PubMed Central. Association of MC1R variants with melanoma risk and interaction with sun exposure: an M-SKIP project Intriguingly, in people who already carry those high-risk MC1R variants, additional sun exposure on chronically exposed areas like the head and neck may not further amplify risk as dramatically, possibly because those genetic variants already push the melanoma pathway forward through UV-independent mechanisms.20PubMed Central. MC1R genotype may modify the effect of sun exposure on melanoma risk in the GEM study
At the tumor level, genetic changes accumulate as a melanoma progresses. Mutations in the BRAF and NRAS genes, two of the most common molecular drivers of melanoma, are found more frequently in invasive tumors than in in situ tumors, and the proportion of mutated cells tends to increase as a melanoma transitions from early horizontal spread to deeper vertical growth.21PubMed Central. Frequencies of NRAS and BRAF Mutations Increase from the Radial to the Vertical Growth Phase in Cutaneous Melanoma This molecular progression underscores why catching melanoma while it is still thin and superficial matters so much: the further the tumor progresses, the more genetically complex and potentially treatment-resistant it becomes.
Screening and Surveillance After Diagnosis
Whether population-wide screening for melanoma does more good than harm remains an open question. In Australia, which has one of the highest melanoma rates in the world, formal population-based screening is not practiced, though substantial opportunistic screening occurs. Most melanomas there are now diagnosed while still in situ, suggesting that early detection efforts are working to some degree. An expert consensus concluded that there is not yet enough evidence on comparative benefits, harms, and costs to justify switching from opportunistic screening to a systematic nationwide program.22Australian and New Zealand Journal of Public Health. Early detection of melanoma: a consensus report from the Australian Skin and Skin Cancer Research Centre Melanoma Screening Summit
Targeted screening of high-risk individuals, on the other hand, has shown promise. A French study found that people in a targeted screening program had melanomas diagnosed at a mean thickness of 0.51 mm, compared with 1.09 mm in people not in the program, though the difference did not reach statistical significance after adjustment.23La Presse Médicale Open. Targeted screening for melanoma after a 5-year follow-up: Comparison of melanoma incidence and lesion thickness at diagnosis in screened (versus unscreened) patients For those already diagnosed and treated, total body photography, where standardized photos of the entire skin surface are taken and then compared over time, improves early detection of new or changing lesions in high-risk individuals.24PubMed Central. The Value of Total Body Photography for the Early Detection of Melanoma: A Systematic Review
The Emotional Weight of a “Good Prognosis” Cancer
Early stage melanoma is often framed by clinicians as a “good news” diagnosis because survival rates are high. But that framing can leave patients feeling that their anxiety is disproportionate or unwelcome. In a study of 51 survivors of localized melanoma (stage 0 through IIA), about three-quarters scored above the clinical threshold for fear of cancer recurrence. Participants described negative emotions surrounding follow-up appointments, the intensity of ongoing skin surveillance, changes they made to their relationship with the sun, and intrusive thoughts about life and death.25PubMed Central. Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma The gap between the statistical prognosis and the lived experience is wide. Some centers have begun trialing structured follow-up programs that combine skin self-examination education with psychosocial support specifically aimed at managing recurrence fears.26PubMed. Employing skin self-examination and fear of cancer recurrence management in early-stage melanoma follow-up: evaluation of the MELACARE intervention in a randomised controlled trial
Melanoma in People With Darker Skin
Melanoma is far more common in non-Hispanic White populations, but when it occurs in people with darker skin tones, it tends to be diagnosed at a more advanced stage and carries worse survival.27PubMed. Melanoma in skin of color: Part I. Epidemiology and clinical presentation Multiple factors drive this disparity: lower rates of screening, less public health messaging directed at people with skin of color, a higher proportion of acral melanoma (which appears on the palms, soles, and under the nails where it is easily missed), socioeconomic barriers to specialty care, and underrepresentation in dermatology training materials.28PubMed. Melanoma in skin of color: Part II. Racial disparities, role of UV, and interventions for earlier detection The bottom line is that melanoma in darker skin is often not UV-driven in the way most public awareness campaigns assume, and the standard ABCDE teaching may be less useful for detecting the subtypes that disproportionately affect these populations.
Acral and mucosal melanomas, the subtypes most often seen in non-White patients, are biologically and clinically distinct from the more common cutaneous forms.29PubMed Central. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective Acral melanoma shows up on hairless skin of the hands and feet or under nails, often as a dark streak or irregularly pigmented patch that can be mistaken for a bruise or fungal infection. Mucosal melanoma arises on internal surfaces like the nasal passages, mouth, or genital area, making it invisible to standard skin checks. Both carry lower BRAF mutation rates than sun-related cutaneous melanomas, which limits some targeted therapy options.
Melanoma in Children and Adolescents
Pediatric melanoma is rare, but it is the most common skin cancer in children. Its clinical appearance often departs from what adults are taught to look for. The standard ABCDE criteria have been adapted for younger patients to account for features like amelanotic (non-pigmented) lesions, lesions that bleed or present as a bump, uniform color rather than the multi-colored appearance typical in adults, any diameter rather than only those above 6 mm, and new lesions arising on previously normal skin.30PubMed Central. Pediatric melanoma: incidence, treatment, and prognosis Treatment largely follows adult guidelines for staging and surgery, but the atypical presentation means pediatric melanomas can go unrecognized longer, since neither parents nor clinicians may be expecting melanoma in a child.31Surgical Oncology Clinics of North America. Pediatric Melanoma Any changing mole in a child, especially one that bleeds or lacks pigment, warrants prompt evaluation even if it does not look like the textbook melanoma most adults picture.